The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for cognition or function in patients with early Alzheimer’s.

In TODAY.com's Expert Tip of The Day, a neurologist explains how playing games that build cognitive speed can protect against ...

In the brain, Alzheimer’s is characterized by two proteins, amyloid beta and tau, that become dysfunctional, forming plaques ...

A steak a day may keep the forgetfulness away. New research suggests that a meat-heavy diet may help ward off dementia, but ...

A powerful new real-world data platform could transform how scientists predict and understand Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD), reports a new study at Columbia ...

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

Small actions today can help reduce your dementia risk.

Some people with the gene did not have expected outcomes if they were heavy meat-eaters ...

The findings could help clinicians use neuropsychiatric symptoms to prepare patients and families for a type of dementia ...

Have you ever wondered how an Alzheimer’s patient literally views the world and what they experience in the confusion? Now, families and caregivers can have the experience through special goggles ...

Now, with the passing of House Bill 565, also known as Jill’s Law, all Mississippians will have access to biomarker testing ...